Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice president of chemistry, manufacturing, and control (CMC). Dr. Salama brings to Vidac more than 20 years of experience in medicinal chemistry, formulation, GMP process chemistry and manufacturing. He will report directly to Vidac’s president and CEO, Dr. Oren M. Becker, and will serve as a member of the company’s executive management team.
“We are happy to welcome Dr. Paul Salama to Vidac Pharma,” said Dr. Oren M. Becker. “Paul is an exceptional expert in all aspects of CMC and will be critical to our success as we work to advance our proprietary pipeline through clinical development.”
Dr. Salama received his Ph.D. in organic chemistry from University of Montreal (Canada) after completion of a M.Sc. in chemical engineering and a B.Sc. in chemistry from the University of Lyon (France). Dr. Salama started his career as a professor at University of Moncton (Canada) where his research focused on the CNS and new organic reaction mechanisms. He subsequently moved to the pharmaceutical industry where he held R&D positions in the GMP process chemistry of APIs and novel formulations development. Among others, he was Director of Manufacturing at Inotek (Israel) and Vice-president of CMC at Chiasma (Israel). Paul has unique expertise in establishing CMC operations from the ground up.
“I am excited to join Vidac Pharma and contribute to the development of its therapeutic pipeline,” said Dr. Salama. “I look forward to developing VDA-1102, a novel VDAC/HK2 modulator, for the treatment of non-melanoma skin cancer.”
About Vidac Pharma
Vidac Pharma is an innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncology and dermatology ailments. Vidac’s breakthrough technology targets the VDAC/HK2 system, unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. This unique technology holds the promise of delivering novel drugs that are both efficacious and well-tolerated by patients. Vidac expects to file an IND with the FDA for clinical studies with VDA-1102 ointment in patients suffering from actinic keratosis in 2015. For more information on Vidac Pharma, please visit www.vidacpharma.com.